Review





Similar Products

ripa binding buffer  (Thermo Fisher)
99
Thermo Fisher ripa binding buffer
Ripa Binding Buffer, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ripa binding buffer/product/Thermo Fisher
Average 99 stars, based on 1 article reviews
ripa binding buffer - by Bioz Stars, 2026-03
99/100 stars
  Buy from Supplier
rna binding buffer  (Zymo Research)
99
Zymo Research rna binding buffer
Rna Binding Buffer, supplied by Zymo Research, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/rna binding buffer/product/Zymo Research
Average 99 stars, based on 1 article reviews
rna binding buffer - by Bioz Stars, 2026-03
99/100 stars
  Buy from Supplier
ripa binding buffer  (Proteintech)
96
Proteintech ripa binding buffer
Ripa Binding Buffer, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ripa binding buffer/product/Proteintech
Average 96 stars, based on 1 article reviews
ripa binding buffer - by Bioz Stars, 2026-03
96/100 stars
  Buy from Supplier
binding buffer  (Thermo Fisher)
99
Thermo Fisher binding buffer
Binding Buffer, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/binding buffer/product/Thermo Fisher
Average 99 stars, based on 1 article reviews
binding buffer - by Bioz Stars, 2026-03
99/100 stars
  Buy from Supplier
annexin v  (Miltenyi Biotec)
99
Miltenyi Biotec annexin v
Cisplatin-responsive primary cell line OSCC43 was grown in two 3D in vitro models for 3 days prior to treatment for 7 days with 10 µM of respective drug combinations, either in free drug formulation or drug-loaded MSNs. Brightfield microscopy was used to capture spheroids ( a ) and BME-embedded organoids ( b ) at beginning of treatment (d0) and at treatment endpoint (d7). ( c , d ) Graph showing spheroid and organoid growth throughout treatment expressed as Log2 of fold change in area at day 7 vs day 3, for OSCC43 spheroids and BME-embedded organoids. mean ± SEM, n = 3. Statistical significance is shown as p-value scores. e ) Representative histograms of flow cytometry analysis of FITC-labeled nanoparticles (MCM41-calc@MSNs, cisPt-ads@MSNs and Pt(IV)-cov@MSNs) within live cells from BME-embedded organoids (BME) and spheroids (SPH) vs an unstained (UNS) control. f ) Representative images of Caspase-3 Immunohistochemistry of treated OSCC43 organoids. Scale bar = 100 µm. g ) Left panel, representative flow cytometry chart illustrating 7-AAD and <t>Annexin</t> <t>V</t> staining of treated OSCC43 cells. g, h ) Graphs showing cell percentage of viable, early and late apoptotic and dead cells from OSCC43 spheroids ( g ) and BME-embedded treated organoids ( h ). mean ± SEM, n = 3, statistical significance is displayed as follows: * = p<0.05; ** = p<0.01; *** = p<0.001; **** = p<0.0001.
Annexin V, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/annexin v/product/Miltenyi Biotec
Average 99 stars, based on 1 article reviews
annexin v - by Bioz Stars, 2026-03
99/100 stars
  Buy from Supplier
dna binding buffer  (Zymo Research)
96
Zymo Research dna binding buffer
Cisplatin-responsive primary cell line OSCC43 was grown in two 3D in vitro models for 3 days prior to treatment for 7 days with 10 µM of respective drug combinations, either in free drug formulation or drug-loaded MSNs. Brightfield microscopy was used to capture spheroids ( a ) and BME-embedded organoids ( b ) at beginning of treatment (d0) and at treatment endpoint (d7). ( c , d ) Graph showing spheroid and organoid growth throughout treatment expressed as Log2 of fold change in area at day 7 vs day 3, for OSCC43 spheroids and BME-embedded organoids. mean ± SEM, n = 3. Statistical significance is shown as p-value scores. e ) Representative histograms of flow cytometry analysis of FITC-labeled nanoparticles (MCM41-calc@MSNs, cisPt-ads@MSNs and Pt(IV)-cov@MSNs) within live cells from BME-embedded organoids (BME) and spheroids (SPH) vs an unstained (UNS) control. f ) Representative images of Caspase-3 Immunohistochemistry of treated OSCC43 organoids. Scale bar = 100 µm. g ) Left panel, representative flow cytometry chart illustrating 7-AAD and <t>Annexin</t> <t>V</t> staining of treated OSCC43 cells. g, h ) Graphs showing cell percentage of viable, early and late apoptotic and dead cells from OSCC43 spheroids ( g ) and BME-embedded treated organoids ( h ). mean ± SEM, n = 3, statistical significance is displayed as follows: * = p<0.05; ** = p<0.01; *** = p<0.001; **** = p<0.0001.
Dna Binding Buffer, supplied by Zymo Research, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/dna binding buffer/product/Zymo Research
Average 96 stars, based on 1 article reviews
dna binding buffer - by Bioz Stars, 2026-03
96/100 stars
  Buy from Supplier
binding buffer  (Multi Sciences (Lianke) Biotech Co Ltd)
96
Multi Sciences (Lianke) Biotech Co Ltd binding buffer
Cisplatin-responsive primary cell line OSCC43 was grown in two 3D in vitro models for 3 days prior to treatment for 7 days with 10 µM of respective drug combinations, either in free drug formulation or drug-loaded MSNs. Brightfield microscopy was used to capture spheroids ( a ) and BME-embedded organoids ( b ) at beginning of treatment (d0) and at treatment endpoint (d7). ( c , d ) Graph showing spheroid and organoid growth throughout treatment expressed as Log2 of fold change in area at day 7 vs day 3, for OSCC43 spheroids and BME-embedded organoids. mean ± SEM, n = 3. Statistical significance is shown as p-value scores. e ) Representative histograms of flow cytometry analysis of FITC-labeled nanoparticles (MCM41-calc@MSNs, cisPt-ads@MSNs and Pt(IV)-cov@MSNs) within live cells from BME-embedded organoids (BME) and spheroids (SPH) vs an unstained (UNS) control. f ) Representative images of Caspase-3 Immunohistochemistry of treated OSCC43 organoids. Scale bar = 100 µm. g ) Left panel, representative flow cytometry chart illustrating 7-AAD and <t>Annexin</t> <t>V</t> staining of treated OSCC43 cells. g, h ) Graphs showing cell percentage of viable, early and late apoptotic and dead cells from OSCC43 spheroids ( g ) and BME-embedded treated organoids ( h ). mean ± SEM, n = 3, statistical significance is displayed as follows: * = p<0.05; ** = p<0.01; *** = p<0.001; **** = p<0.0001.
Binding Buffer, supplied by Multi Sciences (Lianke) Biotech Co Ltd, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/binding buffer/product/Multi Sciences (Lianke) Biotech Co Ltd
Average 96 stars, based on 1 article reviews
binding buffer - by Bioz Stars, 2026-03
96/100 stars
  Buy from Supplier
oligo binding buffer  (Zymo Research)
95
Zymo Research oligo binding buffer
Cisplatin-responsive primary cell line OSCC43 was grown in two 3D in vitro models for 3 days prior to treatment for 7 days with 10 µM of respective drug combinations, either in free drug formulation or drug-loaded MSNs. Brightfield microscopy was used to capture spheroids ( a ) and BME-embedded organoids ( b ) at beginning of treatment (d0) and at treatment endpoint (d7). ( c , d ) Graph showing spheroid and organoid growth throughout treatment expressed as Log2 of fold change in area at day 7 vs day 3, for OSCC43 spheroids and BME-embedded organoids. mean ± SEM, n = 3. Statistical significance is shown as p-value scores. e ) Representative histograms of flow cytometry analysis of FITC-labeled nanoparticles (MCM41-calc@MSNs, cisPt-ads@MSNs and Pt(IV)-cov@MSNs) within live cells from BME-embedded organoids (BME) and spheroids (SPH) vs an unstained (UNS) control. f ) Representative images of Caspase-3 Immunohistochemistry of treated OSCC43 organoids. Scale bar = 100 µm. g ) Left panel, representative flow cytometry chart illustrating 7-AAD and <t>Annexin</t> <t>V</t> staining of treated OSCC43 cells. g, h ) Graphs showing cell percentage of viable, early and late apoptotic and dead cells from OSCC43 spheroids ( g ) and BME-embedded treated organoids ( h ). mean ± SEM, n = 3, statistical significance is displayed as follows: * = p<0.05; ** = p<0.01; *** = p<0.001; **** = p<0.0001.
Oligo Binding Buffer, supplied by Zymo Research, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/oligo binding buffer/product/Zymo Research
Average 95 stars, based on 1 article reviews
oligo binding buffer - by Bioz Stars, 2026-03
95/100 stars
  Buy from Supplier

Image Search Results


Cisplatin-responsive primary cell line OSCC43 was grown in two 3D in vitro models for 3 days prior to treatment for 7 days with 10 µM of respective drug combinations, either in free drug formulation or drug-loaded MSNs. Brightfield microscopy was used to capture spheroids ( a ) and BME-embedded organoids ( b ) at beginning of treatment (d0) and at treatment endpoint (d7). ( c , d ) Graph showing spheroid and organoid growth throughout treatment expressed as Log2 of fold change in area at day 7 vs day 3, for OSCC43 spheroids and BME-embedded organoids. mean ± SEM, n = 3. Statistical significance is shown as p-value scores. e ) Representative histograms of flow cytometry analysis of FITC-labeled nanoparticles (MCM41-calc@MSNs, cisPt-ads@MSNs and Pt(IV)-cov@MSNs) within live cells from BME-embedded organoids (BME) and spheroids (SPH) vs an unstained (UNS) control. f ) Representative images of Caspase-3 Immunohistochemistry of treated OSCC43 organoids. Scale bar = 100 µm. g ) Left panel, representative flow cytometry chart illustrating 7-AAD and Annexin V staining of treated OSCC43 cells. g, h ) Graphs showing cell percentage of viable, early and late apoptotic and dead cells from OSCC43 spheroids ( g ) and BME-embedded treated organoids ( h ). mean ± SEM, n = 3, statistical significance is displayed as follows: * = p<0.05; ** = p<0.01; *** = p<0.001; **** = p<0.0001.

Journal: bioRxiv

Article Title: Overcoming Cisplatin Resistance in 3D Oral Squamous Cell Carcinoma Models via Nanoparticle-Mediated Pt(IV) Drug Delivery

doi: 10.64898/2026.02.22.707247

Figure Lengend Snippet: Cisplatin-responsive primary cell line OSCC43 was grown in two 3D in vitro models for 3 days prior to treatment for 7 days with 10 µM of respective drug combinations, either in free drug formulation or drug-loaded MSNs. Brightfield microscopy was used to capture spheroids ( a ) and BME-embedded organoids ( b ) at beginning of treatment (d0) and at treatment endpoint (d7). ( c , d ) Graph showing spheroid and organoid growth throughout treatment expressed as Log2 of fold change in area at day 7 vs day 3, for OSCC43 spheroids and BME-embedded organoids. mean ± SEM, n = 3. Statistical significance is shown as p-value scores. e ) Representative histograms of flow cytometry analysis of FITC-labeled nanoparticles (MCM41-calc@MSNs, cisPt-ads@MSNs and Pt(IV)-cov@MSNs) within live cells from BME-embedded organoids (BME) and spheroids (SPH) vs an unstained (UNS) control. f ) Representative images of Caspase-3 Immunohistochemistry of treated OSCC43 organoids. Scale bar = 100 µm. g ) Left panel, representative flow cytometry chart illustrating 7-AAD and Annexin V staining of treated OSCC43 cells. g, h ) Graphs showing cell percentage of viable, early and late apoptotic and dead cells from OSCC43 spheroids ( g ) and BME-embedded treated organoids ( h ). mean ± SEM, n = 3, statistical significance is displayed as follows: * = p<0.05; ** = p<0.01; *** = p<0.001; **** = p<0.0001.

Article Snippet: Cells were centrifuged again and resuspended in 1X Binding Buffer for further Annexin V and/or 7AAD staining (Annexin V-FITC Kit #130-092-052, 7-AAD Staining solution #130-111-568, Miltenyi Biotec).

Techniques: In Vitro, Drug Formulation, Microscopy, Flow Cytometry, Labeling, Control, Immunohistochemistry, Staining